Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining AnaptysBio's recent Phase 2b data on Rosnilimab for the treatment of rheumatoid arthritis (RA)

Ticker(s): ANAB, LLY, PFE, ABBV

Who's the expert?

Institution: Rowan Diagnostic Clinic (Private Practice)

Rheumatologist at Rowan Diagnostic Clinic in North Carolina; fellowship trained at University of Massachusetts Medical Center.
Manages 250 patients with rheumatoid arthritis,
Familiar with the rosnilimab phase 2B trial results and can speak to its benefits in the future RA landscape

Interview Goal

This conversation will focus on AnaptysBio investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, demonstrated a best-in-disease profile in patients with moderate-to-severe rheumatoid arthritis (RA). We will discuss the global 424-patient Phase 2b trial.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.